Antisoma value slashed in half after failure of new cancer drug

One of the most advanced drugs to have been developed by a UK biotech has spectacularly failed its clinical trials, sending shares in the company that owns it down 50 per cent and raising questions over the viability of the entire industry.

Antisoma's pill was no more effective against ovarian cancer than a placebo, the company said yesterday, and the product is to be abandoned after 15 years of work costing an estimated £20m. The unequivocal judgement came as a disappointment to those who had hoped a successful outcome would give a boost to investor interest in the fragile biotech sector. It is also a blow to those who bought into a placing and open offer of Antisoma shares at 40p last November. Yesterday, they fell 24.5p to 20p.

More than 420 women in 17 countries took part in the trials and, although the data will be presented at cancer conferences in an attempt to assist understanding of the disease, there is no chance of it being tried in other cancers. Glyn Edwards, the chief executive, said: "It is a definitive result and there is no future for this drug in any of its indications."

The product, codenamed R1549 but previously known as pemtumomab, has had a chequered history. It was originally licensed to Abbott Laboratories, the US pharmaceuticals giant, but Abbott tried to renegotiate terms in 2002 after equivocal data from Phase II trials. It was taken up by Roche when the Swiss giant did its wide-ranging licensing deal with Antisoma in 2002.

Roche said the disappointment would not affect its relationship with Antisoma, which has, in effect, been annexed as a research and development laboratory for the Swiss group. It is funding earlier-stage trials of a breast cancer drug and has options over other products developed by Antisoma. Mr Edwards said Antisoma has more than two years of cash left, and this would most likely be augmented by milestone payments from Roche, but analysts said there was more pressure on him to buy in an extra product to bolster the pipeline of new drug.

The company raised £15.2m last year, which it said at the time would fund the existing pipeline. One investor who bought in at the placing - and sold out yesterday - said he had been buying "an option" on the success of R1549.

The failure of the product prompted handwringing across the UK biotech sector, whose failure to produce blockbuster drugs is often contrasted with the United States. Yesterday, Roche revealed that another of its partners, Genentech of San Francisco, had successfully completed trials of Tarceva for lung cancer.

Rare successes include Humira, a rheumatoid arthritis drug discovered using know-how at Cambridge Antibody Technology, but which is now the subject of a bitter dispute over royalties between CAT and Abbott, which developed it.

David Oxlade, the chief executive of Xenova, whose brain cancer drug Tariquidar was all but abandoned last year, said that the heavy focus investors had been putting on Antisoma's long-awaited trials results highlighted just how thin the UK industry's pipeline is. "The industry is 10-15 years behind the US. It is easier to obtain larger sums of money in the US than in Europe, so their companies have more money to build the depth and breadth of portfolio that allows you to survive the inevitable disappointments."

Andy Smith, the fund manager of the 3i Biosciences investment trust, worries that the biotech sector's modest recent bounce means it is nearer the top of the cycle of investor sentiment than the bottom.

PROMOTED VIDEO
News
newsBear sweltering in zoo that reaches temperatures of 40 degrees
Arts and Entertainment
Brendan O'Carroll has brought out his female alter-ego Agnes Brown for Mrs Brown's Boys D'Movie
filmComedy holds its place at top of the UK box office
News
Ian Thorpe has thanked his supporters after the athlete said in an interview that he is gay
people
Arts and Entertainment
Professor Kathy Willis will showcase plants from the Royal Botanic Gardens at Kew
radioPlants: From Roots to Riches has been two years in the making
Arts and Entertainment
TV The follow-up documentary that has got locals worried
Arts and Entertainment
Eminem's daughter Hailie has graduated from high school
music
Arts and Entertainment
Original Netflix series such as Orange Is The New Black are to benefit from a 'substantial' increase in investment
TVHoax announcement had caused outrage
Life and Style
Swimsuit, £245, by Agent Provocateur
fashion

Diving in at the deep end is no excuse for shirking the style stakes

News
One Direction star Harry Styles who says he has no plans to follow his pal Cara Delevingne down the catwalk.
peopleManagement confirms rumours singer is going it alone are false
News
ebookA unique anthology of reporting and analysis of a crucial period of history
Arts and Entertainment
Curtain calls: Madani Younis
theatreMadani Younis wants the neighbourhood to follow his work as closely as his audiences do
Arts and Entertainment
'Deep Breath' is Peter Capaldi's first full-length adventure as the twelfth Doctor
TVFirst episode of new series has ended up on the internet
Life and Style
Douglas McMaster says the food industry is ‘traumatised’
food + drinkSilo in Brighton will have just six staple dishes on the menu every day, including one meat option, one fish, one vegan, and one 'wild card'
Sport
Mario Balotelli, Divock Origi, Loic Remy, Wilfried Bony and Karim Benzema
transfersBony, Benzema and the other transfer targets
Life and Style
Once a month, waistline watcher Suran steps into a 3D body scanner that maps his body shape and records measurements with pinpoint accuracy
techFrom heart rates to happiness, there is little this fast-growing, self-tracking community won't monitor
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Information Security Manager (ISO 27001, Accreditation, ITIL)

£70000 per annum: Harrington Starr: Information Security Manager (ISO 27001, A...

Biztalk - outstanding opportunity

£75000 - £85000 per annum + ex bens: Deerfoot IT Resources Limited: Biztalk Te...

Trade Desk Specialist (FIX, Linux, Windows, Network Security)

£60000 per annum: Harrington Starr: Trade Desk Specialist (FIX, Linux, Windows...

Service Desk Analyst (Windows, Active Directory, ITIL, Reuter)

£35000 per annum: Harrington Starr: Service Desk Analyst (Windows, Active Dire...

Day In a Page

Iraq crisis: How Saudi Arabia helped Isis take over the north of the country

How Saudi Arabia helped Isis take over northern Iraq

A speech by an ex-MI6 boss hints at a plan going back over a decade. In some areas, being Shia is akin to being a Jew in Nazi Germany, says Patrick Cockburn
The evolution of Andy Serkis: First Gollum, then King Kong - now the actor is swinging through the trees in Dawn of the Planet of the Apes

The evolution of Andy Serkis

First Gollum, then King Kong - now the actor is swinging through the trees in Dawn of the Planet of the Apes
You thought 'Benefits Street' was controversial: Follow-up documentary 'Immigrant Street' has got locals worried

You thought 'Benefits Street' was controversial...

Follow-up documentary 'Immigrant Street' has got locals worried
Refugee children from Central America let down by Washington's high ideals

Refugee children let down by Washington's high ideals

Democrats and Republicans refuse to set aside their differences to cope with the influx of desperate Central Americas, says Rupert Cornwell
Children's books are too white, says Laureate

Children's books are too white, says Laureate

Malorie Blackman appeals for a better ethnic mix of authors and characters and the illustrator Quentin Blake comes to the rescue
Blackest is the new black: Scientists have developed a material so dark that you can't see it...

Blackest is the new black

Scientists have developed a material so dark that you can't see it...
Matthew Barzun: America's diplomatic dude

Matthew Barzun: America's diplomatic dude

The US Ambassador to London holds 'jeans and beer' gigs at his official residence – it's all part of the job, he tells Chris Green
Meet the Quantified Selfers: From heart rates to happiness, there is little this fast-growing, self-tracking community won't monitor

Meet the 'Quantified Selfers'

From heart rates to happiness, there is little this fast-growing, self-tracking community won't monitor
Madani Younis: Five-star reviews are just the opening act for British theatre's first non-white artistic director

Five-star reviews are just the opening act for British theatre's first non-white artistic director

Madani Younis wants the neighbourhood to follow his work as closely as his audiences do
Mrs Brown and her boys: are they having a laugh?

Mrs Brown and her boys: are they having a laugh?

When it comes to national stereotyping, the Irish – among others – know it can pay to play up to outsiders' expectations, says DJ Taylor
Gavin Maxwell's bitter legacy: Was the otter man the wildlife champion he appeared to be?

Otter man Gavin Maxwell's bitter legacy

The aristocrat's eccentric devotion to his pets inspired a generation. But our greatest living nature writer believes his legacy has been quite toxic
Joanna Rowsell: The World Champion cyclist on breaking her collarbone, shattering her teeth - and dealing with alopecia

Joanna Rowsell: 'I wear my wig to look normal'

The World Champion cyclist on breaking her collarbone, shattering her teeth - and dealing with alopecia
Bill Granger recipes: Our chef gives raw ingredients a lift with his quick marinades

Bill Granger's quick and delicious marinades

Our chef's marinades are great for weekend barbecuing, but are also a delicious way of injecting flavour into, and breaking the monotony of, weekday meals
Germany vs Argentina World Cup 2014 preview: Why Brazilians don't love their neighbours Argentina any more

Anyone but Argentina – why Brazilians don’t love their neighbours any more

The hosts will be supporting Germany in today's World Cup final, reports Alex Bellos
The Open 2014: Time again to ask that major question - can Lee Westwood win at last?

The Open 2014

Time again to ask that major question - can Lee Westwood win at last?